AA6216

12/01/2021 - "In this study, we examined the effect of AA6216 on the pulmonary accumulation of segregated-nucleus-containing atypical monocytes (SatMs), which produce tumor necrosis factor (TNF)-α and are involved in murine lung fibrosis. "
12/01/2021 - "The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages."
10/15/2020 - "Finally, we investigated the anti-fibrotic potency of AA6216 on bleomycin-induced lung fibrosis in mice. "
10/15/2020 - "A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung."
10/15/2020 - "In the mouse model of bleomycin-induced pulmonary fibrosis, therapeutic administration of AA6216 significantly reduced fibrosis scores, collagen-stained areas, and TGF-β1 in bronchoalveolar lavage fluid. "

09/05/2021 - "AA6216 also significantly suppressed skin inflammation in three mouse models of dermatitis. "
09/05/2021 - "In this study, we compared the effects of a novel PDE4 inhibitor, AA6216, with those of crisaborole on skin inflammation. "

10/15/2020 - "In the mouse model of bleomycin-induced pulmonary fibrosis, therapeutic administration of AA6216 significantly reduced fibrosis scores, collagen-stained areas, and TGF-β1 in bronchoalveolar lavage fluid. "

09/05/2021 - "In acute and chronic oxazolone-induced dermatitis models, topical AA6216 exhibited stronger inhibitory effects on ear inflammation and cytokine production (TNFα, IL-1β, and IL-4) in skin lesions compared with crisaborole. "

09/05/2021 - "In a Dermatophagoides farinae-induced dermatitis model, AA6216 significantly reduced the dermatitis score, based on the development of erythema/hemorrhage, scarring/dryness, edema, and excoriation/erosion, compared with a clinically used topical AD drug, tacrolimus. "